HORIZON THERAPEUTICS PLC EARNINGS UPDATE
"Importantly, we announced positive topline results from our TEPEZZA clinical trial in low CAS and long-duration TED patients, as well as received FDA approval for an update to the TEPEZZA indication that reinforces the potential benefit of TEPEZZA, regardless of disease activity or duration. "We generated strong first-quarter performance, with double-digit growth for KRYSTEXXA and UPLIZNA, and saw positive trends in TEPEZZA's leading indicators as we exited the first quarter," said Tim Walbert, chairman, president and chief executive officer, Horizon. Named One of Fortune’s 100 Best Companies to Work For® and Ranked as Top Biotechnology/Pharmaceutical Company, Both for Third Consecutive Year -ĭUBLIN, May 03, 2023-( BUSINESS WIRE)-Horizon Therapeutics plc (Nasdaq: HZNP) today announced first-quarter 2023 financial results. Continue to Expect Amgen Transaction to Close in 1H23. Announced Initiation of TEPEZZA Phase 3 Trial in Japan in Chronic/Low CAS TED and Two Daxdilimab Phase 2 Trials in Discoid Lupus Erythematosus and Lupus Nephritis. Announced Positive Topline Data from the Second Population in Dazodalibep Sjögren’s Syndrome Phase 2 Clinical Trial First and Only Phase 2 Sjögren’s Syndrome Trial to Meet the Primary Endpoint in Both Patient Populations Phase 3 Clinical Program Expected to Initiate in 2023. FDA Approval for Updated TEPEZZA Indication to Specify Treatment of TED Patients Regardless of Disease Activity or Duration. Announced Positive Topline Data from TEPEZZA Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED). Cash Position of $2.31 Billion as of Ma-įirst-Quarter and Recent Company Highlights: UPLIZNA® (inebilizumab-cdon) Net Sales of $53.8 Million.
KRYSTEXXA® (pegloticase injection) Net Sales of $187.0 Million. TEPEZZA® (teprotumumab-trbw) Net Sales of $405.3 Million. GAAP Net Income of $54.7 Million Adjusted EBITDA of $ 232.9 Million.
0 kommentar(er)
